Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
20736150

DOI
10.1310/hct1103-133

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Darunavir; Endpoint Determination; Female; HIV Infections /drug therapy /economics /virology; HIV Protease Inhibitors /economics /therapeutic use; HIV-1; Humans; Male; Models, Econometric; RNA, Viral /blood; Ritonavir /economics /therapeutic use; Sulfonamides /economics /therapeutic use; Treatment Outcome; United States

AccessionNumber
22010001626

Date bibliographic record published
15/06/2011